Hypoestoxide inhibits tumor growth in the mouse CT26 colon tumor model

World Journal of Gastroenterology

Volumn 13, Issue 34, 2007, Pages 4586-4588

  Ojo Amaize, Emmanuel A ^a   Cottam, Howard B ^a   Oyemade, Olusola A ^a   Okogun, Joseph I ^a   Nchekwube, Emeka J ^a  

^a Immune Modulation Inc   (United States)

Author keywords

5 Fluorouracil; Colon, Cancer; Hypoestoxide; Mice

Indexed keywords

DITERPENOID; FLUOROURACIL; HYPOESTOXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; COLON CANCER; COLON CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IN VITRO STUDY; LIFESPAN; LOW DRUG DOSE; MELANOMA B16; MONOTHERAPY; MOUSE; NONHUMAN; TUMOR VOLUME;

EID: 34648846473     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i34.4586     Document Type: Article

References (16)

1. Cubas R, Li M, Chen C, Yao Q. Colorectal cancer: new advances in immunotherapy. Cancer Biol Ther 2007; 6: 11-17
2. Norwood AA, Tucci M, Benghuzzi H. A comparison of 5-fluorouracil and natural chemotherapeutic agents, EGCG and thymoquinone, delivered by sustained drug delivery on colon cancer cells. Biomed Sci Instrum 2007; 43: 272-277
3. Braun AH, Achterrath W, Wilke H, Vanhoefer U, Harstrick A, Preusser P. New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 2004; 100: 1558-1577
4. Wilke HJ, Van Cutsem E. Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol 2003; 14 Suppl 2: ii49-ii55
5. Ojo-Amaize EA, Nchekwube EJ, Cottam HB, Bai R, Verdier-Pinard P, Kakkanaiah VN, Varner JA, Leoni L, Okogun JI, Adesomoju AA, Oyemade OA, Hamel E. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action. Cancer Res 2002; 62: 4007-4014
6. Ojo-Amaize EA, Kapahi P, Kakkanaiah VN, Takahashi T, Shalom-Barak T, Cottam HB, Adesomoju AA, Nchekwube EJ, Oyemade CA, Karin M, Okogun J1. Hypoestoxide, a novel anti-inflammatory natural diterpene, inhibits the activity of IkappaB kinase. Cell Immunol 2001; 209: 149-157
7. Ojo-Amaize EA, Nchekwube EJ, Cottam HB, Oyemade CA, Adesomoju AA, Okogun JI. Plasmodium berghei: Antiparasitic effects of orally administered Hypoestoxide in mice. Exp Parasitol 2007; (Epub ahead of print)
8. Adesomoju AA, Okogun JI, Cava MP, Carroll PJ. Hypoestoxide, a new diterpene from Hypoestes rosea (Acanthaceae). Heterocyctes 1983; 20: 2125-2128
9. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke 1990; 21: IV12-IV23
10. Thun MJ, Henley Sj, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-266
11. Sandler RS. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. Important Adv Oncol 1996; 123-137
12. Williams CS, Goldman AP, Sheng H, Morrow JD, DuBois RN. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia 1999; 1: 170-176
13. Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam DH, He J, Kim SJ, Abbruzzese JL, Hamilton SR, Fidler IJ. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005; 65: 3716-3725
14. Flis S, Soltysiak-Pawluczuk D, Jedrych A, Jastrzebski Z, Remiszewska M, Splawinski J. Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest. Anticancer Res 2006; 26: 3033-3041
15. Wada. Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y, Fukushima M. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 2006; 119: 783-791
16. Allegra CJ. New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil. JAMA 1995; 273: 236-239